Kinase Inhibitors

Kinase Inhibitor

P-Glycoprotein Inhibitors

Breast Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="s50"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>NERLYNX (neratinib) immediate release, film-coated tablets for oral administration contain 40 mg of neratinib, equivalent to 48.31 mg neratinib maleate. Neratinib is a member of the 4-anilino quinolidine class of protein kinase inhibitors. The molecular formula for neratinib maleate is C 30H 29ClN 6O 3•C 4H 4O 4and the molecular weight is 673.11 Daltons. The chemical name is (E)-N-{4-[3-chloro-4-(pyridin-2-yl methoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl}-4-(dimethylamino)but-2-enamide maleate, and its structural formula is: <a name="f01"></a><img alt="Structural Formula" src="ner00-0019-01.jpg"/>Neratinib maleate is an off-white to yellow powder with pK as of 7.65 and 4.66. The solubility of neratinib maleate increases dramatically as neratinib becomes protonated at acidic pH. Neratinib maleate is sparingly soluble at pH 1.2 (32.90 mg/mL) and insoluble at approximately pH 5.0 and above (0.08 mg/mL or less). Inactive ingredients: Tablet Core: colloidal silicon dioxide, mannitol, microcrystalline cellulose, crospovidone, povidone, magnesium stearate, and purified water. Coating: red film coat: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide red.</section>

Nerlynx

neratinib

neratinib 40 MG Oral Tablet

neratinib 40 MG Oral Tablet [Nerlynx]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Pharmacy List 

How To Order Nerlynx

Coverage Authorization Request

Coverage Authorization Appeals

Letter of Medical Necessity 

Nerlynx Enrollment Form 

Enroll in Patient Savings Program

Nerlynx Quick Start Program 

Patient Assistance Program 

Clinical Guidelines

Other HCP Resources: Access

Other HCP Resources

About Nerlynx 

Patient Resources 

Doctor Discussion Guide

Patient Brochure - English

Patient Brochure - Spanish

FAQs: Early Stage HER2+ Breast Cancer - English

FAQs: Early Stage HER2+ Breast Cancer - Spanish

FAQs: Metastatic Breast Cancer - English

FAQs: Metastatic Breast Cancer - Spanish 

Puma Patient Lynx Support Program 

Instructions for Use: Early Stage HER2+ Breast Cancer 

Instructions For Use: Metastatic Breast Cancer 